Izlaganje sa skupa
SCREENING FOR DEPRESSION IN POST STROKE PATIENTS
Sophia Ul Haq
; Bedford Hospital NHS Trust, Bedford MK42 9DJ, UK
Christopher Symeon
; Bedford Hospital NHS Trust, Bedford MK42 9DJ, UK
Mark Agius
; Weller Wing, SEPT, Bedford MK42 9DJ, Department of Psychiatry University of Cambridge, UK
Roseanna Brady
; Bedford Hospital NHS Trust, Bedford MK42 9DJ, UK
Sažetak
Background: Depression has a significant prevalence in patients following a stroke. Studies have found rates to be between 25-
54%.
Aims: Within this audit we aimed to ascertain the proportion of patients who have been identified as having depression, and
explore the methods employed to identify depressed patients. We also looked to assess the number of these patients who have been
treated for depression and to explore the medications used for the treatment of depression.
Methods: This audit was conducted in two phases. Initially an audit was conducted to establish the current prevalence, screening
and management of depression in post-stroke patients. Following this, we introduced the PHQ-9 as a screening tool for depression
and a re-audited at four months. In phase 2, All patients admitted to the stoke ward in Bedford hospital between 10/9/09 and
13/12/09 were included in the audit. Patients were screened for depression using the PHQ-9 questionnaire two weeks after
admission.
Results: The incidence of depression within the phase one group was 28%. In 9 of these cases there was no record of mood
assessment or diagnosis of depression in the medical notes. Thirteen out of 60 patients were prescribed psychotropic agents during
their stay. In phase 2, Of the 18 patients screened, 10 patients (56%) scored 5 or above, which according to the scoring system of the
PHQ-9 is indicative of depression. One patient scored 10 indicative of moderate depression and one patient scored 19 indicative of
moderately severe depression.
Discussion: Phase 1 of this audit revealed that there was no formal screening tool in use to identify depression in post stroke
patients. Consequently we found the prevalence to be 28%. This correlates with the lower end of the rate expected within this group
according to the literature. As no screening tool was being used, practice was not in accordance with the standards set by NICE
guidelines. This led us to introduce the PHQ-9 screening tool in phase 2. Following this, we found the prevalence of depression had
increased from 28% to 56%.
Conclusions: These results highlight the importance of formal screening in order to reliably identify patients who have signs of
depression
Ključne riječi
Hrčak ID:
262366
URI
Datum izdavanja:
14.9.2010.
Posjeta: 257 *